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Abstract
Background: Administration of endogenous mediators or exogenous chemicals in migraine patients provoke early
headaches and delayed migraine-like attacks. Although migraine provoking substances are normally vasodilators,
dilation of arterial vessels does not seem to be the sole contributing factor, and the underlying mechanisms of the
delayed migraine pain are mostly unknown. Sustained mechanical allodynia is a common response associated with
the local administration of various proalgesic substances in experimental animals and humans. Here, we investigated
the ability of a series of endogenous mediators which provoke or do not provoke migraine in patients, to cause or not
cause mechanical allodynia upon their injection in the mouse periorbital area.
Methods: Mechanical allodynia was assessed with the von Frey filament assay. Stimuli were given by subcutaneous
injection in the periorbital area of C57BL/6J mice; antagonists were administered by local and systemic injections.
Results: Calcitonin gene related peptide (CGRP), but not adrenomedullin and amylin, pituitary adenylyl cyclase
activating peptide (PACAP), but not vasoactive intestinal polypeptide (VIP), histamine, prostaglandin E2 (PGE2) and
prostacyclin (PGI2), but not PGF2α, evoked a dose-dependent periorbital mechanical allodynia. The painful responses
were attenuated by systemic or local (periorbital) administration of antagonists for CGRP (CLR/RAMP1), PACAP (PAC-1),
histamine H1, PGE2 (EP4), and PGI2 (IP) receptors, respectively.
Conclusions: The correspondence between substances that provoke (CGRP; PACAP, histamine, PGE2, PGI2), or do not
provoke (VIP and PGF2α), migraine-like attacks in patients and periorbital allodynia in mice suggests that the study of
allodynia in mice may provide information on the proalgesic mechanisms of migraine-provoking agents in humans.
Results underline the ability of migraine-provoking substances to initiate mechanical allodynia by acting on peripheral
terminals of trigeminal afferents.
Keywords: Migraine, calcitonin gene related peptide, pituitary adenylyl cyclase activating peptide, prostaglandin,
histamine, vasoactive intestinal polypeptide, allodynia
Background
Migraine is a pain disorder that affects about 15% of the
adult population worldwide. Thus, the burden of mi-
graine is enormous in terms of suffering, disability,
healthcare, and social and economic costs [1]. For these
reasons, migraine is ranked among the most disabling
medical conditions [2]. Although considerable progress
has been made in the development of new treatment
options [3, 4], our current understanding of the mecha-
nisms underlying migraine pain is incomplete. Migraine
attacks are elicited by a variety of provoking agents [5],
and this peculiar feature provides an opportunity to ex-
plore disease mechanisms by endogenous mediators or
exogenous chemicals that provoke migraine-like attacks
in patients [6].
A prototypical example of a migraine-provoking agent is
glyceryl trinitrate (GTN). Occupational exposure to, or
treatment with, organic nitrates has long been known to
provoke headaches [7–10]. Typically, GTN causes an
early, mild and short-lived headache minutes after admin-
istration, followed by a remarkably delayed migraine-like
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attack hours later [9, 10]. The ability of GTN to provoke
the mild/early headache is temporally associated with the
short-lived (<10 min) release of nitric oxide (NO) [11] and
ensuing vasodilation [12]. However, the prolonged
migraine-like attacks typically begin with a remarkable
delay of hours, underlying the temporal dissociation be-
tween the early vasomotor response and the delayed
proalgesic effect [6, 13, 14]. Thus, the vascular response
can hardly explain the delayed migraine-like attack, which,
therefore, implicates additional mechanisms. Recently, we
reported that GTN administration in mice evokes an early
and short-lived (10 minutes) vasodilatation due to a direct
vascular action of NO, and a delayed and prolonged (8
hours) periorbital mechanical allodynia (PMA) that is in-
dependent from vascular changes and is due to the activa-
tion of an oxidative stress-mediated pathway in the soma
of trigeminal primary sensory neurons [15]. We also ob-
served that GTN-evoked PMA in mice exhibits a tem-
poral pattern [15] similar to the migraine-like attacks in
patients, which are characterized by delayed onset and
prolonged duration [6].
In the last three decades, rigorous studies with random-
ized, double blind and crossover designs have been under-
taken, resulting in a systematic investigation of the ability
of a series of endogenous mediators or exogenous chemi-
cals to provoke early headaches and delayed migraine-like
attacks [6]. Vasodilatation has been proposed as the
underlying mechanism of migraine headaches [16]. Not-
ably, both intra and extracranial artery vasodilatation or
only intracranial artery vasodilatation have been reported
in association with spontaneous migraine attacks [17–19].
Although vasodilatation is elicited by a majority of the mi-
graine provoking agents [6, 14, 20], the vascular response
does not seem essential for generating delayed migraine
attacks, as robust vasodilators, such as the vasoactive in-
testinal polypeptide (VIP) or adrenomedullin, do not in-
duce migraine [21, 22]. Thus, an experimental animal
model that explores the correspondence between the
pain-producing ability of mediators that provoke migraine
might be useful for a better understanding of the
pro-migraine action of such mediators.
Here, we have investigated whether a series of en-
dogenous mediators, which have been found to provoke
or not provoke migraine-like attacks in patients, elicit or
do not elicit delayed and prolonged PMA after their in-
jection in the periorbital skin of mice. Provocation tests
in humans are usually performed by systemic adminis-
tration of the stimulus [6]. However, in the present study
in mice the local administration was purposively chosen
to investigate the interaction between the various media-
tors and the peripheral terminals of trigeminal nocicep-
tors. These mediators include calcitonin gene-related
peptide (CGRP), adrenomedullin, amylin, pituitary ade-
nylyl cyclase activating peptide (PACAP), VIP, histamine,
prostaglandin E2 (PGE2), prostacyclin (PGI2) and prosta-
glandin F2α (PGF2α). The receptor type implicated in the
PMA evoked by each mediator was also studied. A close
correspondence was found between agents that provoke/
not provoke delayed migraine in patients and PMA in
mice. Thus, the study of PMA in mice may provide in-
formation on the proalgesic mechanisms that, in
humans, result in the development of migraine-like at-
tacks provoked by endogenous mediators and exogenous
chemicals.
Methods
Animals
In vivo experiments were carried out according to the
European Union (EU) guidelines and Italian legislation
(DLgs 26/2014, EU Directive application 2010/63/EU)
for animal care (research permit #194/2015-PR). C57BL/
6J mice (male, 20-22 g, 6-7 weeks old; Envigo, Milan,
Italy) were used. Animals were housed in a temperature
(20-24°C)- and relative humidity (45-65%) -controlled
vivarium, maintained on a 12-hour dark/light cycle
(light off from 7.00 PM to 7.00 AM), and with free ac-
cess to food and water. Animal studies were reported in
compliance with the ARRIVE guidelines [23]. The total
number of C57BL/6J mice used was 486. Group size of
n=6 animals for behavioural experiments were deter-
mined using G*Power (v3.1) [24] to detect a minimum
difference between paired means of 1.4 standard devia-
tions (or 1.8 standard deviations between groups) in
post-hoc tests with type 1 and 2 error rates of 5 and
20%, respectively [15]. Allocation concealment was per-
formed using a randomization procedure (http://
www.randomizer.org/). Experiments were done in a
quiet, temperature-controlled (20-24°C) room between
9.00 AM and 5.00 PM and were performed by an oper-
ator blinded to drug treatment. At the end of each ex-
periment, mice were euthanized with inhaled CO2 plus
10-50% O2.
Reagents
CGRP, amylin, PACAP, VIP, PGF2α, olcegepant, astemizole,
ER819762 and Ro1138452 were from Tocris Bioscience
(Bristol, UK); adrenomedullin, PACAP6-38, PGE2, PGI2
and histamine were from Sigma Aldrich (Milan, Italy); the
mouse monoclonal anti-CGRP antibody (clone [4901])
and the inactive immunoglobulin (mouse monoclonal
IgG2a) were from Abcam (Cambridge, UK)
Behavioural experiments
Treatment protocols
C57BL/6J mice were injected subcutaneously in the peri-
orbital area (p.orb., 10 μl/site) with CGRP, adrenomedul-
lin, amylin, PACAP, VIP, histamine, PGE2, PGI2 and
PGF2α (0.15, 1.5 and 15 nmol) or their vehicles (0.9%
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NaCl). The subcutaneous injection was performed uni-
laterally on the right side of the periorbital area. The
mouse was restrained by the double handed manual re-
straint method [25]. Briefly, the mouse was lifted by the
base of the tail and placed on a solid surface with one
hand and the tail was pulled back. Then, it was quickly
and firmly picked up by the scruff of the neck behind
the ears with the thumb and index finger of the other
hand. In this way, the mouse face was constrained, and
the operator was able to inject the tested compound. In-
jection was performed as quickly as possible by a single
operator, with only minimal animal restraint.
Some mice were pre-treated (30 minutes before the
stimuli) with intraperitoneal (i.p., 10 ml/kg) olcegepant
(1 μmol/kg corresponding to 0.869 mg/kg), astemizole
(4 μmol/kg corresponding to 1.8 mg/kg), ER819762 (60
μmol/kg corresponding to 29.4 mg/kg) or their vehicle
(4% dimethyl sulfoxide, DMSO, and 4% tween 80 in
0.9% NaCl) and intravenous (i.v., 1 ml/kg) PACAP6-38
(12 nmol/kg corresponding to 48 μg/kg) and Ro1138452
(30 μmol/kg corresponding to 10.4 mg/kg), or their ve-
hicle (0.9% NaCl). Other mice received locally (p.orb., 10
μl, 30 minutes before the stimuli) olcegepant (4 nmol/
site), astemizole (10 nmol/site), ER819762 (10 nmol/
site), or their vehicle (4% DMSO and 4% tween 80 in
0.9% NaCl) and PACAP6-38 (240 pmol/site) and
Ro1138452 (10 nmol/site), or their vehicle (0.9% NaCl),
or a mouse monoclonal anti-CGRP antibody or, as a
control, a mouse monoclonal IgG2a (both, 60 pmol/site).
In another set of experiments, C57BL/6J mice received
intraplantar (i.pl., 20 μl, 30 minutes before the stimuli)
injections of olcegepant (4 nmol/site), astemizole (10
nmol/site), ER819762 (10 nmol/site), or their vehicle
(4% DMSO and 4% tween 80 in 0.9% NaCl), or
PACAP6-38 (240 pmol/site) and Ro1138452 (10 nmol/
site), or their vehicle (0.9% NaCl).
Acute nociceptive test
Immediately after the p.orb. injections, mice were placed
inside a plexiglass chamber and spontaneous nociception
was assessed by measuring the time (seconds) that the
animal spent face rubbing the injected area with its paws
[26] over the next 10 minutes. The p.orb. injection with
vehicles produced nociceptive behaviour for a maximum
of 3 seconds.
Periorbital mechanical allodynia
The measurement of PMA was performed by using the
up-and-down paradigm as described previously [27, 28]
in the same mice in which acute nociceptive responses
were monitored for 10 minutes after the stimulus. Ani-
mals were allocated in a restraint apparatus designed for
the evaluation of periorbital mechanical thresholds. The
apparatus consists in an individual clear three-walled
plexiglass box (4 H × 4 W x 10 L cm) with an opening
for the tail and one for the head and front paws, located
on a platform to allow the operator to access to the peri-
orbital area. The box size allowed for head and forepaw
movements but prevented the animal from turning
around inside it (Fig 1A). One day before the first behav-
ioural observations, mice were habituated to the appar-
atus. PMA was evaluated in the periorbital region over
the rostral portion of the eye (i.e., the area of the perior-
bital region facing the sphenoidal rostrum) of the mice
[29] (Fig 1a), before (basal threshold) and after (0.5, 1, 2,
4, 6, 8 hours) treatment.
The day of the experiment, after 20 minutes of adapta-
tion inside the chamber, a series of 7 Von Frey filaments
in logarithmic increments of force (0.02, 0.04, 0.07, 0.16,
0.4, 1.0 and 1.4 g) were applied to the periorbital area
perpendicular to the skin, with sufficient force to cause
slight buckling, and held for approximately 5 seconds to
elicit a positive response. The response was considered
positive by the following criteria: mouse vigorously
stroked its face with the forepaw, head withdrawal from
the stimulus, or head shaking. The stimulation initiated
with the 0.16 g filament. Absence of response after 5
seconds led to the use of a filament with increased
weight, whereas a positive response led to the use of a
weaker (i.e. lighter) filament. Six measurements were
collected for each mouse or until four consecutive posi-
tive or negative responses occurred. The 50% mechanical
withdrawal threshold (expressed in g) was then calcu-
lated from these scores by using a δ value of 0.205, pre-
viously determined.
Statistical Analysis
All data were expressed as mean ± s.e.m. Statistical ana-
lysis was performed by the unpaired two-tailed Student’s
t-test for comparisons between two groups. Group
means for single factor experiments were analysed with
a one-way ANOVA, while behavioural experiments with
repeated measures employed a two-way mixed model
ANOVA, first to determine the presence of an inter-
action effect, and then to compare the control and
treated groups of mice at each time point tested. In both
cases, post-hoc comparisons employed the Bonferroni
criterion to maintain the experiment-wise error rate at
5%. To avoid uncertainties that would follow from the
use of these parametric methods on data that may not
attain an interval level of measurement, as well as the
potential violation of other ANOVA assumptions, in-
cluding that of normal sampling distribution, analyses
were repeated using non-parametric methods. Both
methods led to similar conclusions, and we presented
only the parametric analyses, which maintain the ori-
ginal, and more intuitive, units of measure. Statistical
analyses were performed on raw data using Prism 5
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GraphPad software (GraphPad Software Inc., San Diego,
CA, USA), as well as IBM SPSS (v.25, IBM Corp.,
Armonk, NY, USA). P<0.05 was considered statistically
significant.
Results
CGRP, adrenomedullin, amylin
CGRP, amylin and adrenomedullin belong to the larger cal-
citonin family of peptides, which activate, with different po-
tencies, a series of receptors resulting from the multiple
combinations of the 3 forms of the calcitonin (CT, further
divided into the a, b and δ(1-47)b subtypes) receptor and
the CT receptor-like receptor (CLR) with the 3 forms of
receptor-activity-modifying proteins (RAMPs) [30]. Al-
though CGRP can bind to all these receptor complexes, it
exhibits a higher affinity for the RAMP1/CLR [30]. Adreno-
medullin binds with higher potency to the RAMP2-3/CLR
and amylin to the RAMP1/CT(a) and the RAMP1-2/CT(b)
[30]. Whereas periorbital (p.orb., 10 μl/site) injection of
CGRP (0.15, 1.5 and 15 nmol/site), even at the highest dose,
did not evoke an acute spontaneous nociceptive response
(Fig. 1b), it did cause a robust, dose-dependent and sus-
tained PMA (Fig. 1c). The prolonged PMA was present at
0.5 hour, peaked at 2 hours and declined, to return to base-
line values, 6 hours after CGRP injection. Systemic intra-
peritoneal (i.p., 1 μmol/kg) or local (p.orb., 4 nmol/site), but
not intraplantar (i.pl., 20 μl, 4 nmol/site) injection (30 mi-
nutes before CGRP) of the CGRP receptor antagonist, olce-
gepant, prevented PMA (Fig. 1d-f). Furthermore, p.orb. (10
μl) pretreatment (30 min before) with a monoclonal
anti-CGRP antibody (60 pmol/site), but not with the in-
active mouse monoclonal IgG2a, also prevented the devel-
opment of PMA induced by p.orb. CGRP (Fig. 1g).
Local (p.orb., 10 μl) administration of adrenomedullin
or amylin at the same pro-allodynic dose of CGRP (1.5 or
15 nmol/site), was unable to produce any measurable
acute nociceptive response, even at the highest dose.
Adrenomedullin or amylin also failed to produce PMA
over the entire period of observation (6 hours) (Fig. 1h, i).
PACAP and VIP
The members of the family of the PACAP and VIP vaso-
active peptides act on VPAC-1 and VPAC-2 receptors with
comparable affinity, whereas the PAC-1 receptor isoform
has 100-fold higher affinity for PACAP [31, 32]. Local
(p.orb., 10 μl) injection of PACAP (0.15, 1.5 and 15 nmol/
Fig. 1 a Photograph of restraint apparatus and von Frey monofilament used for evaluating periorbital mechanical allodynia (PMA) and drawing
indicating the region where periorbital von Frey stimulus was applied during testing. b Subcutaneous injection in the periorbital area (p.orb.,
10 μl/15 nmol/site) of CGRP does not cause spontaneous nociceptive behaviour. c Dose- and time-dependent PMA evoked by p.orb. Injection of
CGRP (10 μl/0.15–15 nmol/site). d-f Effect of pretreatment with intraperitoneal (i.p. 1 μmol/kg), p.orb. (10 μl/4 nmol/site) and intraplantar (i.pl.,
20 μl/4 nmol/site) olcegepant on PMA evoked by CGRP (p.orb., 10 μl/1.5 nmol/site). g Effect of pretreatment with a monoclonal anti-CGRP
antibody (mAb anti-CGRP) or mouse monoclonal IgG2a (IgG2a) (both p.orb., 10 μl/60 pmol/site) on PMA evoked by CGRP (p.orb., 10 μl/1.5 nmol/
site). Adrenomedullin or amylin injection (p.orb., 10 μl/1.5–15 nmol/site) does not evoke spontaneous nociceptive behaviour (h) or PMA (i). C57BL/
6J mice were used. Veh is the vehicle of CGRP (b-g), adrenomedullin or amylin (h, i), and veh1 is the vehicle of olcegepant (d-f). Arrows indicate
time of CGRP, adrenomedullin or amylin administration. Olcecepant, mAb anti-CGRP or IgG2a were given 30 min before the stimulus. Error bars
indicate mean ± s.e.m., n = 6 mice per group. *P < 0.05 vs. Veh or Veh + Veh1, §P < 0.05 vs. Veh1 + CGRP; two-way ANOVA with Bonferroni post
hoc correction
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site), which did not provoke any detectable spontaneous
nociceptive behaviour even at the highest dose, induced a
marked, dose-dependent and sustained (1-6 hours) PMA
(Fig. 2a, b). Intravenous (i.v., 1 ml/kg, 12 nmol/kg) or p.orb.
(10 μl, 240 pmol/site), but not i.pl. (20 μl, 240 pmol/site),
pretreatment with the selective PACAP receptor antagonist,
PACAP6-38, prevented PACAP-induced PMA (Fig. 2c, e).
VIP (1.5 or 15 nmol/site, p.orb.) was unable to produce ei-
ther acute nociception or PMA (Fig. 2f, g).
Histamine
Histamine is a ubiquitous mediator released from mast
cells, enterochromaffin-like cells and neurons, impli-
cated in pathophysiological responses such as arousal
state, allergy, inflammation, itch and pain [33–35]. Its
actions are mediated by four distinct receptors, the H1,
H2, H3 and H4 receptors [36]. Local injection (p.orb.,
10μl) of histamine (0.15, 1.5 and 15 nmol/site) was un-
able to produce any spontaneous acute nociception, even
at the highest dose administered, but induced a
dose-dependent and sustained (4-6 hours) PMA (Fig. 3a,
b). Systemic (i.p., 10 ml/kg, 4 μmol/kg) or p.orb. (10 μl,
10 nmol/site), but not i.pl. (20 μl, 10 nmol/site) pretreat-
ment with the histamine H1 receptor antagonist, astemi-
zole, prevented histamine-induced PMA (Fig. 3c-e).
PGE2, PGI2, PGF2α
Prostanoids are ubiquitous mediators which play a major
role in a large variety of physiological responses and
pathological process, including inflammation and pain
[37]. Cyclooxygenase inhibition by non-steroidal
anti-inflammatory drugs (NSAIDs), which prevents the
transformation of arachidonic acid into the inactive
prostaglandin precursor, prostaglandin H2 (PGH2), is a
mainstay of the acute migraine attack, thus implicating
prostaglandins in migraine pain [38, 39]. PGE2
administration in the mouse paw is known to evoke
spontaneous acute nociception [40]. Accordingly, we
found that PGE2 (0.15, 1.5 and 15 nmol/site), but not
PGI2 (0.15, 1.5 and 15 nmol/site) or PGF2α (1.5-15
nmol/site) injection into the mouse periorbital skin elic-
ited a marked spontaneous nociceptive response (Fig. 4a,
f, k). Furthermore, injection of both PGE2 and PGI2, but
not PGF2α, evoked a dose-dependent sustained (0.5-6
hours) PMA (Fig. 4b, g, k). Pretreatment with i.p. (10
ml/kg, 60 μmol/kg) and p.orb. (10 μl, 10 nmol/site), but
not i.pl. (20 μl, 10 nmol/site) prostaglandin receptor 4
(EP4) antagonist, ER819762, prevented PGE2-induced
spontaneous nociception and PMA (Fig. 4a, c-e). Pre-
treatment with i.v. (1 ml/kg, 30 μmol/kg) and p.orb., (10
μl, 10 nmol/site), but not i.pl. (20 μl, 10 nmol/site) an-
tagonist for the prostacyclin receptor (IP), Ro1138452,
prevented PGI2-induced PMA (Fig. 4h-j). Conversely,
Ro1138452 (i.v., 30 μmol/kg) did not affect spontaneous
nociception and PMA evoked by PGE2 and ER819762
(i.p., 60 μmol/kg) did not affect PMA evoked by PGI2
(Fig. 4a, c, h).
Discussion
The members of the calcitonin family of peptides acti-
vate a variety of receptors deriving from the
dimerization of CLR or CL with RAMP proteins. Adre-
nomedullin, which stimulates the combinations of the
CLR with RAMP2 or RAMP3 with a potency higher
than CGRP (AM1 and AM2 receptor, respectively), and
amylin, which is equipotent to CGRP on the receptor
combinations formed by the three CT subtypes with
RAMP1, RAMP2 or RAMP3, failed to evoke allodynia.
A possible effect of amylin and adrenomedullin on the
RAMP1/CLR, or of CGRP on the different combinations
of receptors for amylin and adrenomedullin has been
claimed to contribute to the pro-migraine action of
Fig. 2 a PACAP periorbital (p.orb., 10 μl/15 nmol/site) injection does not evoke spontaneous nociceptive behaviour. b Dose- and time-dependent
periorbital mechanical allodynia (PMA) evoked by p.orb. Injection of PACAP (10 μl/0.15–15 nmol/site). c-e Effect of pretreatment with intravenous
(i.v., 12 nmol/kg), p.orb. (10 μl/240 pmol/site) or intraplantar (i.pl., 20 μl/240 pmol/site pmol) PACAP6–38 on PMA evoked by PACAP (p.orb., 10 μl/
1.5 nmol/site). VIP injection (p.orb., 10 μl/1.5 and 15 nmol/site) does not evoke spontaneous nociceptive behaviour (f) or PMA (g). C57BL/6J mice
were used. Veh is the vehicle of PACAP (a-e) or VIP (f, g) and veh1 is the vehicle of PACAP6–38 (c-e). Arrows indicate time of PACAP or VIP
administration. PACAP6–38 was given 30 min before the stimulus. Error bars indicate mean ± s.e.m., n = 6 mice per group. *P < 0.05 vs. Veh or
Veh + Veh1, §P < 0.05 vs. Veh1 + PACAP; two-way ANOVA with Bonferroni post hoc correction
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CGRP or its receptor [30]. As previously reported in the
mouse hindpaw [41] and periorbital area [15], we con-
firm that CGRP causes a robust and sustained mechan-
ical allodynia, which is attenuated by both systemic and
local administration of the selective RAMP1/CLR
(CGRP receptor) antagonist, olcegepant. The observa-
tion that, under the same experimental conditions nei-
ther adrenomedullin nor amylin evoked PMA negates
the implication of their preferred receptors in
CGRP-mediated pain-like responses. Furthermore, the
present results do not support the hypothesis that amy-
lin or adrenomedullin act on RAMP1/CLR to evoke
pain-like responses. Previous results that CGRP adminis-
tration to migraineurs induced delayed migraine-like at-
tacks [42], whereas adrenomedullin was found to be
inactive [22], strengthened and excluded the role in mi-
graine mechanism of CGRP and adrenomedullin, re-
spectively. The present findings on the calcitonin related
peptides, recapitulating human results, support the pre-
dictive value of mouse PMA in investigating pain mech-
anisms of migraine.
Clinical trials with anti CGRP or anti RAMP1/CLR
monoclonal antibodies, while showing excellent efficacy
and safety profile, also indicate that a subset of migraine
patients either do not respond or have a partial benefit
[4, 43, 44]. This observation suggests that additional
mechanisms and mediators contribute to migraine pain,
thus prompting the study of substances other than CGRP.
PGE2 and PGI2, two prostaglandins that induce headaches
and migraine-like attacks in humans [45–48], elicited PMA
in mice. In contrast, PGF2α, a prostaglandin, which was un-
able to evoke migraine-like attack in patients [49], failed to
elicit PMA in mice. The use of selective antagonists for the
EP4 and IP receptors showed that PGE2 and PGI2 caused
allodynia exclusively by activating the respective preferred
receptor. This conclusion suggests that in humans PGE2
and PGI2 elicit migraine-like attacks by acting on EP4 and
IP receptors, respectively. As reported previously, in the
mouse hindpaw [40], PGE2 was the sole compound among
all the presently investigated substances that evoked an
early spontaneous nociceptive response, which, similarly to
allodynia, was abated by EP4 receptor antagonism. How-
ever, given that only one of the migraine-provoking sub-
stances elicited spontaneous nociception, the significance of
such early non-evoked pain-like responses for migraine
pain mechanism remains unclear.
Histamine, a key proinflammatory and allergic mediator
with a proalgesic role provokes migraine-like attacks in pa-
tients [50–52]. Furthermore, anecdotical reports and clin-
ical investigations [53] have proposed the use of increasing
doses of histamine to desensitize the pain-producing mech-
anism in migraine patients. Present data show that, by tar-
geting the H1 receptor subtype, histamine evokes PMA in
mice and provides indirect support to the contribution of
the H1 receptor, rather than H2 receptors [51], in provoking
migraine [52], and to the desensitization process that is
supposed to ameliorate migraine [53]. It should be under-
lined that, despite the ability of histamine to sensitise noci-
ceptors via H1 receptor activation, the H1-antagonists were
not always effective in reducing migraine [54].
VIP and PACAP, which belong to the glucagon/secre-
tin family of regulatory peptides, stimulate three distinct
receptors: the PAC-1, selectively activated by PACAP,
and the VPAC-1 and VPCA-2, which are equipotently
activated by both PACAP and VIP. The observation that
PACAP, but not VIP, elicited allodynia, suggests that the
Fig. 3 a Histamine periorbital (p.orb., 10 μl/15 nmol/site) injection does not evoke spontaneous nociceptive behaviour. b Dose- and time-
dependent periorbital mechanical allodynia (PMA) evoked by p.orb. Injection of histamine (10 μl/0.15–15 nmol/site). c-e Effect of pretreatment
with intraperitoneal (i.p., 4 μmol/kg), p.orb. (10 μl/10 nmol/site) or intraplantar (i.pl., 20 μl/10 nmol/site) astemizole on PMA evoked by histamine
(p.orb., 10 μl/1.5 nmol/site). C57BL/6J mice were used. Veh is the vehicle of histamine and veh1 is the vehicle of astemizole (c-e). Arrows indicate
time of histamine administration. Astemizole was given 30 min before histamine. Error bars indicate mean ± s.e.m., n = 6 mice per group. *P < 0.05
vs. Veh or Veh + Veh1, §P < 0.05 vs. Veh1 + histamine; two-way ANOVA with Bonferroni post hoc correction
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PACAP/PAC-1 is the sole pathway implicated in gener-
ating pain-like responses. PACAP and VIP are both
vasodilator substances [55, 56]. The ability of PACAP,
and not VIP, to cause allodynia in mice and
migraine-like attacks in humans [21, 57], supports the
hypothesis that vasodilatation is not per se a major factor
contributing to allodynia in mice and migraine pain in
humans. These findings are in line with previous obser-
vations that PACAP, but not VIP, causes delayed activa-
tion and sensitization of central trigeminovascular
neurons via activation of the PAC1 receptor [58]. The
implication of mast cells has been proposed in the path-
way activated by PACAP to elicit pain. Mast cells may
release PACAP [59], and PACAP, via a hitherto unchar-
acterized receptor, degranulates mast cells [60]. The
present model could be used to further explore local
mechanisms that, activated by PACAP and implicating
mast cells, result in pain responses.
The underlying mechanism that promotes migraine at-
tacks is unclear. Clinical investigation with small mol-
ecule CGRP receptor antagonists underscores the key
role of CGRP in the genesis of migraine pain [4, 61].
However, the specific site(s) of the proalgesic action of
CGRP in migraine pain remains elusive. Recent clinical
trials with monoclonal antibodies that block CGRP or its
receptor [43, 44], underline the hypothesis that the pain
produced by CGRP during migraine attacks originates at
a peripheral site, outside the blood brain barrier. How-
ever, the precise location of such a peripheral site is un-
certain. The observation that PMA was attenuated only
if antagonists were given locally, close to (p.orb.), but
not at distance from (i.pl.) the site where the respective
agonists were injected, indicates that the anatomical site
where pain hypersensitivity initially originates is the ter-
minal region of peripheral trigeminal fibres.
Differences may exist between the trigeminal fibres of the
skin and those innervating meningeal blood vessels [62, 63]
that are possibly implicated in migraine pathogenesis.
Nevertheless, the local subcutaneous injection of stimuli
was adopted purposively to selectively investigate the inter-
action between pro-migraine mediators and peripheral
terminals of trigeminal nociceptors and to minimize con-
founding factors, deriving from the systemic administration
or the surgical procedures required for dural application of
the stimuli. The old dispute regarding the contribution of
the peripheral or central nervous system to allodynia and
Fig. 4 a Effect of pretreatment with intraperitoneal (i.p., 60 μmol/kg) ER819762 or intravenous (i.v., 30 μmol/kg) Ro1138452 on the spontaneous
nociceptive behaviour evoked by periorbital (p.orb., 10 μl/15 nmol/site) injection of PGE2. b Dose- and time-dependent periorbital mechanical
allodynia (PMA) evoked by p.orb. Injection of PGE2 (10 μl/0.15–15 nmol/site). c Effect of pretreatment with ER819762 (i.p., 60 μmol/kg) and
Ro1138452 (i.v., 30 μmol/kg) on PMA evoked by PGE2 (p.orb., 10 μl/1.5 nmol/site). d, e Effect of pretreatment with p.orb. (10 μl/10 nmol/site) or
intraplantar (i.pl., 20 μl/10 nmol/site) ER819762 on PMA evoked by PGE2 (p.orb., 10 μl/1.5 nmol/site). f PGI2 (p.orb., 10 μl/15 nmol/site) does not
evoke spontaneous nociceptive behaviour. g Dose- and time-dependent PMA evoked by PGI2 (p.orb., 10 μl/0.15–15 nmol/site). h Effect of
pretreatment with Ro1138452 (i.v., 30 μmol/kg), and ER819762 (i.p., 60 μmol/kg) on PMA evoked by PGI2 (p.orb., 10 μl/1.5 nmol/site). i, j Effect of
pretreatment with p.orb. (10 μl/10 nmol/site) or i.pl. (20 μl/10 nmol/site) Ro1138452 on PMA evoked by PGI2 (p.orb., 10 μl/1.5 nmol/site). k PGF2α
(p.orb., 10 μl/1.5–15 nmol/site) does not evoke spontaneous nociceptive behaviour or PMA. C57BL/6J mice were used. Veh is the vehicle of PGE2
(a-e), PGI2 (f-j) or PGF2α (k) and veh1 is the vehicle of ER819762 (d, e), Ro1138452 (i, j) or a combination of vehicles of ER819762 and Ro1138452
(a, c, h). Arrows indicate time of PGE2, PGI2 or PGF2α administration. ER819762 and Ro1138452 were given 30 min before PGE2 or PGI2. Error bars
indicate mean ± s.e.m., n = 6 mice per group. *P < 0.05 vs. Veh or Veh + Veh1, §P < 0.05 vs. Veh1 + PGE2 or Veh1 + PGI2; one- or two-way ANOVA
with Bonferroni post hoc correction
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hyperalgesia [64–67] has not yet been completely resolved.
The present investigation reports a condition of hypersensi-
tivity that originates peripherally in the periorbital area of
mice, but by no means implies that central neural pathways
do not contribute to sustain allodynia. However, pathways
and mechanisms regulating mechanical hypersensitivity in
the central nervous system are not the object of the
present study. Clinical investigation shows that, while
blockade of the CGRP system provides benefit in a
large proportion of patients, a subset of migraineurs
appears to be resistant [43, 44], thus suggesting that
additional mediators and mechanisms contribute to
migraine pain. The ability to evoke PMA in mice
adds support to the role of additional migraine pro-
voking mediators in spontaneous pain attacks.
Conclusions
The major finding of the present study is the strict cor-
respondence between mediators that provoke migraine
in patients and evoke periorbital allodynia in mice. The
same correspondence was observed between mediators
that do not provoke migraine in patients and do not
evoke allodynia in mice. An additional relevant finding
is that, although most of the pro-allodynic substances
tested in the present study are vasodilators, two robust
vasodilators, VIP and adrenomedullin, did not evoke
allodynia, thus indicating that vascular activity is not per se
sufficient to elicit pain. Cutaneous allodynia is frequently
reported by migraine patients during the attack [68, 69].
However, it should be considered that migraine-like attacks
induced by provoking substances are characterized by de-
layed and prolonged spontaneous, non-evoked pain. There-
fore, mechanical allodynia cannot recapitulate the complete
spectrum of the pain modalities experienced by migraineurs
during their attacks. Nevertheless, disclosing the mecha-
nisms used by the different mediators, and particularly
CGRP, to evoke delayed and sustained mechanical allodynia
in mice may provide insights for a better understanding of
the mechanisms by which the same substances generate
migraine pain in patients.
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